Phase III Digital Therapeutics Trial: KIOS App vs Standard Care in Opioid Use Disorder — What Addiction Medicine Specialists Need to Know

References

1. 1.Brorson, H. H., Ajo Arnevik, E., Rand-Hendriksen, K., & Duckert, F. (2013). Drop-out from addiction treatment: a systematic review of risk factors. Clinical Psychology Review, 33(8), 1010-1024. https://doi.org/10.1016/j.cpr.2013.07.007
2. 2.Maricich, Y. A., Xiong, X., Gerwien, R., Kuo, A., Velez, F., Imbert, B., Meier, E., Brame, A., Sorensen, J. L., & Cantrell, C. R. (2021). Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Current Medical Research and Opinion, 37(8), 1271-1278. https://doi.org/10.1080/03007995.2021.1907900
3. 3.Samples, H., Williams, A. R., Olfson, M., & Crystal, S. (2018). Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. Journal of Substance Abuse Treatment, 95, 9-17. https://doi.org/10.1016/j.jsat.2018.04.009
4. 4.Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. https://doi.org/10.1136/bmj.j1550
5. 5.University of Texas Health Science Center at San Antonio. (2024). Evaluation of KIOS in a 12-week Randomized Controlled Trial. ClinicalTrials.gov. NCT06212557. https://clinicaltrials.gov/study/NCT06212557